(DOC) Healthpeak Properties - Overview
Stock: Outpatient Medical, Lab, CCRC, Joint Venture Loans
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 7.34% |
| Yield on Cost 5y | 7.37% |
| Yield CAGR 5y | -12.85% |
| Payout Consistency | 96.7% |
| Payout Ratio | 12.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 25.5% |
| Relative Tail Risk | -2.39% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.50 |
| Alpha | -19.01 |
| Character TTM | |
|---|---|
| Beta | 0.464 |
| Beta Downside | 0.648 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.89% |
| CAGR/Max DD | -0.20 |
Description: DOC Healthpeak Properties January 03, 2026
Healthpeak Properties, Inc. (NYSE: DOC) is an S&P 500-listed REIT that owns, operates, and develops a diversified portfolio of U.S. healthcare real estate across three core segments: outpatient medical facilities, laboratory spaces, and continuing-care retirement communities (CCRCs). Structured as an umbrella partnership REIT (UPREIT), the company holds the vast majority of its assets through its operating subsidiary, Healthpeak OP, and reports a total of 703 property interests as of September 30 2025, including 530 outpatient, 139 lab, 15 CCRC, and 19 non-reportable assets.
Key performance indicators from the most recent fiscal year show a funds-from-operations (FFO) of approximately $1.10 per share and an occupancy rate near 96% across the portfolio, reflecting strong demand for outpatient and lab space. The REIT’s leverage ratio remains around 45% of total assets, a level that analysts consider moderate given the sector’s sensitivity to interest-rate movements. Demographic trends-particularly the aging U.S. population and the shift toward outpatient care-continue to drive demand for Healthpeak’s property types, while the company’s dividend yield hovers near 5.5%.
For a deeper dive into Healthpeak’s valuation metrics, you might explore the detailed analyst toolkit on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 71.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.53 > 1.0 |
| NWC/Revenue: 3.12% < 20% (prev 4.10%; Δ -0.98% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.26b > Net Income 71.3m |
| Net Debt (9.90b) to EBITDA (1.60b): 6.18 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (696.0m) vs 12m ago -0.51% < -2% |
| Gross Margin: 22.48% > 18% (prev 0.60%; Δ 2188 % > 0.5%) |
| Asset Turnover: 14.02% > 50% (prev 13.54%; Δ 0.47% > 0%) |
| Interest Coverage Ratio: 1.78 > 6 (EBITDA TTM 1.60b / Interest Expense TTM 305.2m) |
Altman Z'' -1.20
| A: 0.00 (Total Current Assets 1.07b - Total Current Liabilities 985.3m) / Total Assets 20.34b |
| B: -0.29 (Retained Earnings -5.95b / Total Assets 20.34b) |
| C: 0.03 (EBIT TTM 544.1m / Avg Total Assets 20.14b) |
| D: -0.44 (Book Value of Equity -5.27b / Total Liabilities 12.03b) |
| Altman-Z'' Score: -1.20 = CCC |
Beneish M -1.68
| DSRI: 0.82 (Receivables 684.3m/794.0m, Revenue 2.82b/2.70b) |
| GMI: 2.68 (GM 22.48% / 60.20%) |
| AQI: 1.00 (AQ_t 0.93 / AQ_t-1 0.93) |
| SGI: 1.05 (Revenue 2.82b / 2.70b) |
| TATA: -0.06 (NI 71.3m - CFO 1.26b) / TA 20.34b) |
| Beneish M-Score: -1.68 (Cap -4..+1) = CCC |
What is the price of DOC shares?
Over the past week, the price has changed by -2.26%, over one month by +2.72%, over three months by -2.31% and over the past year by -9.91%.
Is DOC a buy, sell or hold?
- StrongBuy: 10
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DOC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19.9 | 18% |
| Analysts Target Price | 19.9 | 18% |
| ValueRay Target Price | 17.4 | 3.3% |
DOC Fundamental Data Overview February 07, 2026
P/E Forward = 67.1141
P/S = 4.1075
P/B = 1.555
P/EG = 4.0809
Revenue TTM = 2.82b USD
EBIT TTM = 544.1m USD
EBITDA TTM = 1.60b USD
Long Term Debt = 8.77b USD (from longTermDebt, last quarter)
Short Term Debt = 1.08b USD (from shortLongTermDebt, last quarter)
Debt = 10.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.90b USD (from netDebt column, last quarter)
Enterprise Value = 21.57b USD (11.59b + Debt 10.44b - CCE 467.5m)
Interest Coverage Ratio = 1.78 (Ebit TTM 544.1m / Interest Expense TTM 305.2m)
EV/FCF = 17.97x (Enterprise Value 21.57b / FCF TTM 1.20b)
FCF Yield = 5.56% (FCF TTM 1.20b / Enterprise Value 21.57b)
FCF Margin = 42.51% (FCF TTM 1.20b / Revenue TTM 2.82b)
Net Margin = 2.53% (Net Income TTM 71.3m / Revenue TTM 2.82b)
Gross Margin = 22.48% ((Revenue TTM 2.82b - Cost of Revenue TTM 2.19b) / Revenue TTM)
Gross Margin QoQ = -87.20% (prev 58.64%)
Tobins Q-Ratio = 1.06 (Enterprise Value 21.57b / Total Assets 20.34b)
Interest Expense / Debt = 0.77% (Interest Expense 80.6m / Debt 10.44b)
Taxrate = 4.72% (6.03m / 127.8m)
NOPAT = 518.5m (EBIT 544.1m * (1 - 4.72%))
Current Ratio = 1.09 (Total Current Assets 1.07b / Total Current Liabilities 985.3m)
Debt / Equity = 1.39 (Debt 10.44b / totalStockholderEquity, last quarter 7.50b)
Debt / EBITDA = 6.18 (Net Debt 9.90b / EBITDA 1.60b)
Debt / FCF = 8.25 (Net Debt 9.90b / FCF TTM 1.20b)
Total Stockholder Equity = 7.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.35% (Net Income 71.3m / Total Assets 20.34b)
RoE = 0.91% (Net Income TTM 71.3m / Total Stockholder Equity 7.80b)
RoCE = 3.28% (EBIT 544.1m / Capital Employed (Equity 7.80b + L.T.Debt 8.77b))
RoIC = 3.04% (NOPAT 518.5m / Invested Capital 17.03b)
WACC = 4.36% (E(11.59b)/V(22.03b) * Re(7.62%) + D(10.44b)/V(22.03b) * Rd(0.77%) * (1-Tc(0.05)))
Discount Rate = 7.62% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 12.77%
[DCF Debug] Terminal Value 87.32% ; FCFF base≈1.15b ; Y1≈1.28b ; Y5≈1.67b
Fair Price DCF = 56.46 (EV 49.14b - Net Debt 9.90b = Equity 39.24b / Shares 695.0m; r=5.90% [WACC]; 5y FCF grow 12.79% → 2.90% )
EPS Correlation: -33.73 | EPS CAGR: 13.23% | SUE: 0.27 | # QB: 0
Revenue Correlation: 94.71 | Revenue CAGR: 10.28% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.06 | Chg30d=-0.027 | Revisions Net=-1 | Analysts=3
EPS current Year (2026-12-31): EPS=0.20 | Chg30d=-0.050 | Revisions Net=-1 | Growth EPS=+412.8% | Growth Revenue=+0.9%
EPS next Year (2027-12-31): EPS=0.21 | Chg30d=-0.045 | Revisions Net=-1 | Growth EPS=+5.0% | Growth Revenue=+3.7%